- Report
- December 2022
- 118 Pages
Global
From €3960EUR$4,500USD£3,448GBP
- Report
- April 2025
- 182 Pages
Global
From €3960EUR$4,500USD£3,448GBP
- Report
- April 2025
- 200 Pages
Global
From €6996EUR$7,950USD£6,091GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1320EUR$1,500USD£1,149GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1320EUR$1,500USD£1,149GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1100EUR$1,250USD£958GBP
- Report
- April 2023
- 147 Pages
Global
From €4355EUR$4,949USD£3,792GBP
- Report
- March 2023
- 162 Pages
Global
From €3167EUR$3,599USD£2,758GBP
- Report
- May 2024
- 133 Pages
Global
From €3519EUR$3,999USD£3,064GBP
- Report
- May 2024
- 137 Pages
Global
From €3519EUR$3,999USD£3,064GBP
- Report
- October 2023
- 162 Pages
Global
From €2200EUR$2,500USD£1,916GBP
- Report
- October 2024
- 210 Pages
Global
From €2200EUR$2,500USD£1,916GBP
- Report
- June 2024
- 211 Pages
Global
From €4395EUR$4,995USD£3,827GBP
- Report
- June 2024
- 200 Pages
Global
From €4395EUR$4,995USD£3,827GBP
- Report
- October 2023
- 75 Pages
India
From €2948EUR$3,350USD£2,567GBP
- Report
- March 2023
- 75 Pages
Spain
From €2948EUR$3,350USD£2,567GBP
- Report
- January 2023
- 78 Pages
Africa
From €2948EUR$3,350USD£2,567GBP
- Report
- January 2023
- 78 Pages
Thailand
From €2948EUR$3,350USD£2,567GBP
- Report
- January 2023
- 70 Pages
Bangladesh
From €2948EUR$3,350USD£2,567GBP
- Report
- October 2022
- 72 Pages
Iran
From €2948EUR$3,350USD£2,567GBP

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers.
Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more